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Tumours are known to be able to successfully escape the host
immune system by one or both of the two general mechanisms: a
loss of surface antigens to become invisible to immune cells or an
attack on immune cells to disable their antitumour functions. Both
phenomena are now recognised as significant contributors to
cancer growth and disease progression (Whiteside, 2002). While
the concept of surface antigen loss was recognised many years ago,
and tumour cells became useful tools to evaluate this process, its
acceptance as a bona fide mechanism of tumour escape required
considerable persuasion. Similarly, tumour-mediated immune
suppression remains a controversial issue among tumour im-
munologists, although modern molecular immunology has identi-
fied at least a dozen mechanisms attributed to tumours and
responsible for immune cell dysfunction in tumour-bearing hosts
(Whiteside, 2002).
More than 25 years ago, reports appeared in the scientific
literature describing isolation from supernatants of human tumour
cell lines of membraneous vesicles (MV) expressing molecular
markers characteristic of tumour plasma membranes (Taylor et al,
1983a). In cultures of murine B16 melanoma cells, for example, the
isolated MV were found to contain glycoprotein profiles identical
to those in the tumour cell membrane (Taylor et al, 1988). Careful
biochemical analysis of MV isolated from the ascites of patients
with ovarian carcinoma showed the presence of placental alkaline
phosphatase (PLAP), CD44 and TSG101 protein, all present in the
tumour as well (Taylor and Gercel-Taylor, 2004). These and other
studies not only confirmed the identity of membrane-associated
markers with those on the tumour cell surface but also indicated
that an energy-dependent process of ‘shedding’ was responsible for
their appearance in cell supernatants as well as sera and other body
fluids of patients with cancer (Taylor et al, 1988; Taylor and
Gercel-Taylor, 2005). From the beginning, the presence of MV,
which are estimated to be from 50 to 100nm in diameter, has been
linked to cancer progression, largely because of their abundance in
body fluids of cancer patients with advanced disease and their
paucity or absence in body fluids of normal individuals. The
importance of the shedding phenomenon for tumour progression
took some years to appreciate, and recent discoveries of a variety
of biologically active molecules, such as a membrane form of Fas
ligand (FasL), APO2/TRAIL, CD44 or major histocompatibility
complex (MHC) class I antigens, in association with MV provide a
reasonable explanation for their involvement in immune suppres-
sion. It appears that MV shed from the tumour surface and
isolated from tumour cell supernatants or body fluids of cancer
patients have profound inhibitory effects on immune cells in vitro,
including blocking of signalling, proliferation, cytotoxicity and
induction of apoptosis (Taylor et al, 2003; Kim et al, 2004). In vivo,
the development of tumour-related anergy could be linked to the
appearance in the patients’ sera of shed tumour membrane
fragments (Taylor et al, 1983b).
However, tumour cells are not the only source of MV in body
fluids, as extracellular shedding is commonly encountered in other
cell types, among them activated immune cells. This would argue
for the existence in body fluids of a variety of MV, representing
different cellular origins. Indeed, quite independently but in
parallel to then on-going biochemical and structural characteriza-
tion of tumour-derived MV, investigators discovered vesicular
structures produced by maturing reticulocytes and named them
‘exosomes’ (Johnstone et al, 1987). Since their first description in
late 1980s, exosomes have steadily occupied attention of biologists,
and much information has accumulated in regard to their
structure and molecular attributes (Thery et al, 2002). Exosomes
contain a mix of proteins associated with antigen presentation
(MHC and costimulatory molecules and heat shock proteins);
microvesicular structure (cytoskeleton-associated tubulin, actin-
binding proteins, annexins); exosome targeting (the tetraspanin
family, lactadherin and Mac-1); and apoptosis (FasL, APO2/
TRAIL).
Exosomes became a focus of particular interest to cancer
investigators when Zitvogel and co-workers reported that dendritic
cells (DC) generated from peripheral blood of cancer patients
produce and release exosomes, which accumulate tumour-rejec-
tion antigens and thus can be used as antitumour vaccines (Thery
et al, 1999). To a casual observer, exosomes and MV seemed to
represent similar tumour antigen-enriched structures, which were
being isolated from DC or sera, respectively, of patients with
cancer by methods involving ultracentrifugation but performed
under quite different conditions. However, exosomes were being
viewed as convenient vehicles for the delivery of DC-processed
tumour antigens to T cells by some investigators (Chaput et al,
2003), while others looked at tumour-derived MV as harbingers of
T-cell death by virtue of their ability to induce apoptosis of
activated T cells mediated by membrane-associated FasL and
related molecules (Andreola et al, 2002; Kim et al, 2004).
Convincing evidence was mustered by both sides, and thus one
was tempted to conclude that DC and tumour cells shed
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explanation, but as we now learn, not a correct one. In this issue of
the journal, the Taylors, who incidentally, are responsible for MV
discovery, convincingly argue that exosomes and MV are one and
the same entity based on molecular and biochemical evidence
(Taylor and Gercel-Taylor, 2005). These investigators obtained
ascites or serum specimens from women with ovarian carcinoma,
split these specimens into two aliquots and used them to isolate (1)
exosomes by the gradient density centrifugation and (2) MV by the
two-step chromatography/centrifugation procedure. Then, exo-
somes and MV were systematically compared for their protein
profiles by SDS–PAGE, protein markers expression by Western
immunoblots, and biologic activity in functional assays measuring
expression of signalling molecules or DNA fragmentation induced
by MV in T lymphocytes. The results are unambiguous: exosomes
and MV had identical protein profiles and mediated the same
immunoinhibitory activities in vitro. These results are significant
because they: (a) close the gap between two parallel research fields,
placing future investigations of exosomes and MV on the same
platform; (b) give credence to the fact that MV/exosomes are
involved in immune regulation in cancer and (c) open a way for
creative novel approaches to the use of these structures in future
therapy of cancer.
While the characterization of MV/exosomes isolated from sera
and body fluids of patients with various neoplasias continues, a
number of concerns remain. For example, it has not been proven
that in tumour-bearing subjects, tumour is the only or the major
source of origin for these structures. It could be argued, for
example, that activated immune cells are the major contributor. It
is also possible that once shed from tumour and/or immune cells,
these structures rearrange or coalesce to form ‘hybrid’ vesicles
with molecular profiles of various contributing cells. Differences in
the molecular composition of MV in patients with the same
malignancies could exist, accounting for variability in their
biologic activity. The status of MV in patients cured of their
disease (NED) is not clear, but it appears that they persist in the
circulation long after therapy. Taylor et al (1983b) reported that
the serum level of MV increases prior to the clinical diagnosis of
recurrent disease. Our own data suggest that the FasL content of
MV in patients with head and neck cancer may be related to
disease activity and prognosis, in that patients with Stage III
and IV disease and those with lymph node metastases had MV in
the sera with the highest content of the 41kDa FasL (Kim et al,
2004).
MV isolated from body fluids of patients with various
malignancies are enriched in the membrane-bound molecules able
to induce apoptosis in activated immune cells. This provides an
explanation for spontaneous apoptosis of T lymphocytes observed
in the peripheral circulation of patients with cancer (Kim et al,
2004). CD8þ effector T cells are preferentially targeted for
apoptosis. Differential sensitivity of CD8þ and CD4þ T cells to
MV-induced, Fas-mediated apoptosis could be perhaps explained
by an incomplete cleavage of caspase-8 to its active form reported
to occur in Th2 cells. Protection from MV-incduced apoptosis by
cytokine- or chemokine-mediated activation of phosphatidylino-
sitol-3-kinase (PI3K) in these cells might contribute to their
relative resilience.
An important aspect of the MV/exosome biology concerns their
general role in immune tolerance. Thus, MV have been isolated
from maternal blood and are known to be produced by placental
cells (Taylor and Black, 1987). Further, a recent paper by Morelli
et al (2004) suggests that in mice, blood-borne MHC class I-rich
allogeneic exosomes are targeted, internalised and processed by
DC in the spleen and other organs. These exosomes are processed
by CD8aþ DC in a way that induces unresponsiveness of T cells to
the presented alloantigens. These experiments introduce a
possibility that donor-derived exosomes delivered intravenously
could induce donor-specific transplant tolerance. In a different
context, Licia Rivoltini reports that melanoma cell line-derived
exosomes interfere with DC maturation and with tumour-antigen
presentation by these DC to T cells in in vitro assays (personal
communication). Thus, the role exosomes play in DC-mediated T-
cell responses is not yet clear. DC appear to be able to edit exosome
processing, with a final outcome directed toward tolerance rather
than immune stimulation, depending perhaps on the route of MV
administration or on their antigenic mosaic. MV/exosomes may
function as messengers for positive or negative intercellular
signalling and transfer of molecules between T cells, DC and the
tumour or foreign graft. Caution is, therefore, needed in using MV/
exosomes as antitumour vaccines for fear of inducing tolerance.
Dissection of immunogenic vs tolerogenic signals delivered by
these structures to DC or T lymphocytes is an important future
challenge. There is evidence that MV can directly downregulate
expression of the TcR-associated z chain as well as expression of
JAK3 in Jurkat cells co-incubated with MV. While these data
confirm suppressive effects of MV on activated T cells, a better
understanding of the molecular mechanisms and signalling
pathways targeted by MV/exosomes are necessary.
MV/exosomes are a perfect example of the efficiency of tumours
in orchestrating their escape from the host immune system. By
adapting a ubiquitous process of membrane shedding, tumours are
able to accomplish the loss of those antigens that may be
immunogenic and capable of signalling to immune cells as well
as induce dysfunction or death of immune effector cells located at
a distance from the tumour microenvironment. A better under-
standing of this process, and especially of molecular mechanisms
involved in exosome/MV interactions with immune cells, is likely
to provide significant insights into the phenomenon of tumour-
related immune tolerance. In addition, insights into the MV/
exosome biology are likely to offer opportunities for the
development of novel approaches to immunotherapy of cancer,
graft rejection and other diseases.
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